Publication details
Czech Hizentra Noninterventional Study With Rapid Push: Efficacy, Safety, Tolerability, and Convenience of Therapy With 20% Subcutaneous Immunoglobulin
| Authors | |
|---|---|
| Year of publication | 2019 |
| Type | Article in Periodical |
| Magazine / Source | Clinical Therapeutics |
| MU Faculty or unit | |
| Citation | |
| Web | http://dx.doi.org/10.1016/j.clinthera.2019.08.013 |
| Doi | http://dx.doi.org/10.1016/j.clinthera.2019.08.013 |
| Keywords | Nonmedical switch; Primary antibody deficiency; Rapid push; Subcutaneous immunoglobulin replacement therapy; Treatment satisfaction |
| Description | Purpose: Immunoglobulin substitution therapy is an essential therapeutic approach for patients with primary antibody deficiencies. Different methods of administration, including intravenous immunoglobulin (WIG) or subcutaneous immunoglobulin (SCIG) preparations, provide effective and tolerable treatment and enable the adjustment of therapy to patients' needs. A new 20% SCIG represents a new therapeutic option and a new route of administration using rapid-push application. The aim of the Czech Hizentra Noninterventional Study With Rapid Push (CHHINSTRAP) is to evaluate patient satisfaction with as well as the tolerability and efficacy of nonmedical switch to 20% SCIG from previous treatment with WIG or SCIG and rapid push as a new way to administer SCIG. CHHINSTRAP is the first Phase W, noninterventional, open-label, prospective, multicentric study of this type conducted in Central and Eastern Europe. Methods: Primary end points, including efficacy, adverse effects, convenience of use, and overall satisfaction, were evaluated by Treatment Satisfaction Questionnaire for Medication version II. Secondary end points, such as serum IgG trough levels, infusion duration, number of application sites, frequency of infections, related hospital admissions, and antibiotic consumption, were obtained from patients at each follow-up visit. Findings: Together, 50 eligible patients with primary antibody deficiency were switched from SCIG or WIG to an equivalent dose of 20% SCIG and were followed up for 12 months during 5 consecutive visits. The results indicate that patients switched from previous WIG or SCIG preparations had significantly higher serum trough IgG levels and a lower incidence of infections and related events, such as hospital admissions or consumption of antibiotics. These findings were also reflected in gradually increasing convenience of use and overall satisfaction reported by patients. Apart from duration of application, no differences were found between patients previously receiving SCIG or WIG. Moreover, our study found a high level of safety of 20% SCIG rapid push, which was comparable to other preparations and application methods. (C) 2019 Elsevier Inc. All rights reserved. |